Navigation Links
Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference

- Phase I data from XL880, Phase II data from XL999 studies scheduled for presentation during oral, poster sessions -

SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that data from clinical trials of the company's investigational compounds XL880 and XL999 will be presented at the 2007 American Society of Clinical Oncology Annual Meeting (ASCO), which is being held June 1 to 5 in Chicago, Illinois.

    -- Data from the Phase I trials of XL880 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics oral

       abstract presentation session at 9:00 a.m. CT on Saturday, June 2, in

       room E354b. (Abstract #3526)


    -- Data from the Phase II trials of XL999 will be presented and discussed

       during the Developmental Therapeutics: Molecular Therapeutics poster

       session at 8:00 a.m. on Sunday, June 3, in S Hall A2. (Abstract #3591)


Additionally, four abstracts from Phase I studies of XL184 (Abstract #14031), XL647 (Abstract #14044) and Phase II studies of XL880 (Abstract #15601) and XL999 (Abstract #18112) will be published in abstract form but will not be presented at the meeting.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

CONTACT: investors, Charles Butler, Director, Corporate Communications,+1-650-837-7277, , or media, Soleil Maxwell Harrison,Senior Manager, Corporate Communications, +1-650-837-7012, both of Exelixis, Inc. cbutler@exelixis.com sharrison@exelixis.com

Web site: http://www.exelixis.com/

Ticker Symbol: (NASDAQ-NMS:EXEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
2. OXiGENE Abstracts Published in ASCO Program
3. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
5. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Scientific Results Presented At ECCMID Demonstrate Well- Differentiated Profile of Basileas Two Phase III Anti- infective Compounds
9. EntreMed Presents Mechanism Data for Its Three Lead Oncology Compounds
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
Breaking Medicine News(10 mins):